In the United States<unk>  is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. In the European Union it is indicated in adults aged 18 years and older with type 2 diabetes mellitus: * to improve glycemic control when metformin with or without sulphonylurea (SU) and either<unk>  or dapagliflozin does not provide adequate glycemic control. * when already being treated with metformin and<unk>  and dapagliflozin.
Dapagliflozin/saxagliptin/metformin
Empagliflozin/linagliptin/metformin
Canagliflozin/metformin
Empagliflozin/metformin
Pioglitazone/metformin
Empagliflozin/linagliptin
Insulin degludec/liraglutide
Dapagliflozin/metformin